DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today provided business updates and outlined anticipated growth drivers for 2026, including progress across its commercial programs and clinical development initiatives. “MannKind closed 2025 on a high note, marked by milestones ...

Core Points - MannKind Corporation, in partnership with Alfred E. Mann Charities and The Diabetes Link, launched the Centennial Al Mann Scholarship to honor the legacy of its founder Alfred E. Mann, distributing $100,000 in scholarship funds to support young adults living with diabetes pursuing higher education in life sciences [1][2][8] - The scholarship program aims to empower students aged 18-22 with type 1 or type 2 diabetes, providing up to $10,000 per recipient, distributed in annual installments of $2,500 [3][4] - The initiative reflects Alfred E. Mann's commitment to improving human life through medical advancement and philanthropy, continuing his vision of giving back to the community [2][5] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions, particularly in cardiometabolic and orphan lung diseases [6][7] - The company has a history of developing breakthrough medical devices and treatments, including the inhaled insulin product Afrezza, which was brought to market with a significant investment of nearly $1 billion by Alfred E. Mann [5][6] Partnership and Community Impact - The partnership with The Diabetes Link aims to expand access to higher education for young adults with diabetes, addressing the rising costs of college and easing financial burdens [5][12] - The Diabetes Link is a national nonprofit organization dedicated to empowering young adults living with diabetes through peer support and resources, envisioning a future where they thrive in their personal and professional lives [12]

Core Insights - MannKind Corporation announced that the FDA has accepted the supplemental biologics license application (sBLA) for Afrezza, seeking approval for use in children and adolescents with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026 [1][8] Company Overview - MannKind Corporation is a biopharmaceutical company focused on innovative solutions for chronic diseases, particularly in cardiometabolic and orphan lung diseases, including diabetes [6][7] Product Information - Afrezza is a rapid-acting inhaled human insulin indicated for improving glycemic control in adults with diabetes mellitus, and it has been available for adults since June 2014 [3][4] - If approved for pediatric use, Afrezza would be the first needle-free insulin option for children in over 100 years [8] Clinical Study Details - The sBLA is based on the Phase 3 INHALE-1 study, which involved children and adolescents aged 4-17, comparing Afrezza with multiple daily injections (MDI) [2][8] - The study's six-month topline results were reported in December 2024, and full results will be presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) in early November [2]

Core Insights - MannKind Corporation will showcase its inhaled insulin product, Afrezza, at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025, in Chicago [1][5] - Dr. Michael J. Haller will present results from the INHALE-1 clinical trial, focusing on inhaled insulin treatment for children and adolescents aged 4-17 [2][3] - MannKind plans to submit a Supplemental Biologics License Application for a pediatric indication for Afrezza in mid-2025, following the release of topline results from the full pediatric data set in Q2 2025 [5] Company Overview - MannKind Corporation specializes in developing and commercializing inhaled therapeutic products and delivery devices for endocrine and orphan lung diseases [6][7] - The company aims to address serious unmet medical needs through innovative dry-powder formulations and inhalation devices, providing rapid and convenient delivery of medications [7] Upcoming Events - The ADA's Scientific Sessions will feature a symposium titled "Future Ready," where breakthrough advancements in pediatric Type 1 diabetes care will be discussed [3] - MannKind will host a booth (1617) at the event for scientific exchange and to showcase its products [4]